Clinical Endpoint Bioequivalence study [Regulatives / Guidelines]

posted by sury – India, 2019-04-09 06:19 (923 d 16:34 ago) – Posting: # 20133
Views: 2,187

» You're referring to the draft guidance on miconazole buccal tablets, right ? Would be easier for us if you could say so straight away and link the guidance...

yes, i am actually referring to the miconazole buccal tablets drug

» For the statistical analysis the draft guidance refers to another draft guidance, on adapalene + benzoyl peroxyde. Did you read it ? Did you see anywhere a mention of log-transformation ? And why are you changing acceptance limits of -0.20 to +0.20 into 80.00 - 120.00 ?

There is no where in the draft guidance on what data (Untransformed and Log Transformed) to conduct the statistical Analysis.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

Activity
 Admin contact
21,737 posts in 4,546 threads, 1,543 registered users;
online 20 (0 registered, 20 guests [including 3 identified bots]).
Forum time: Monday 22:53 CEST (Europe/Vienna)

Law is mind without reason.    Aristotle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5